Teleflex Gross Profit
The Gross Profit of Teleflex (TFX) as of Jul 27, 2026 is 1.12 B USD. In the previous year, Gross Profit was 1.70 B USD — a change of -34.18% (lower).
Get this data via API
Financial Data API
Gross Profit
1.12 BUSD
YoY
-34.18%
Last updated:
Gross Profit of Teleflex is 2026 1.12 B USD. Gross Profit of Teleflex was 2025 1.70 B USD. It decreases by -34.18% lower compared to the previous year.
The Teleflex Gross Profit history
3 Years
10 Years
25 Years
Max
GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2023
55.37 base
Jan 1, 2024
55.87 base
Jan 1, 2025
56.24 base
Jan 1, 2026 (e)
48.99 base
Jan 1, 2027 (e)
46.70 base
Jan 1, 2028 (e)
27.60 base
Jan 1, 2029 (e)
24.84 base
Jan 1, 2030 (e)
23.41 base
| YEAR | GROSS MARGIN (%) |
|---|---|
| 2030 est | 23.41 |
| 2029 est | 24.84 |
| 2028 est | 27.60 |
| 2027 est | 46.70 |
| 2026 est | 48.99 |
| 2025 | 56.24 |
| 2024 | 55.87 |
| 2023 | 55.37 |
| 2022 | 54.86 |
| 2021 | 55.15 |
| 2020 | 52.22 |
| 2019 | 54.29 |
| 2018 | 56.55 |
| 2017 | 54.60 |
| 2016 | 53.33 |
| 2015 | 52.19 |
| 2014 | 51.22 |
| 2013 | 49.46 |
| 2012 | 48.24 |
| 2011 | 47.02 |
| 2010 | 44.07 |
| 2009 | 43.07 |
| 2008 | 39.83 |
| 2007 | 35.17 |
| 2006 | 29.25 |
Access this data via the Eulerpool API
Teleflex Revenue
Teleflex Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
2.97 B USD
506.31 M USD
356.33 M USD
Jan 1, 2024
3.05 B USD
159.02 M USD
69.68 M USD
Jan 1, 2025
1.99 B USD
255.80 M USD
-905.64 M USD
Jan 1, 2026 (e)
2.29 B USD
876.34 M USD
314.79 M USD
Jan 1, 2027 (e)
2.40 B USD
903.67 M USD
498.29 M USD
Jan 1, 2028 (e)
4.06 B USD
1.04 B USD
890.65 M USD
Jan 1, 2029 (e)
4.51 B USD
1.08 B USD
994.11 M USD
Jan 1, 2030 (e)
4.79 B USD
1.14 B USD
1.08 B USD
Teleflex Margins
Teleflex stock margins
The Teleflex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Teleflex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Teleflex.
3 Years
5 Years
10 Years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
55.37 %
17.02 %
11.98 %
Jan 1, 2024
55.87 %
5.22 %
2.29 %
Jan 1, 2025
56.24 %
12.84 %
-45.45 %
Jan 1, 2026 (e)
56.24 %
38.30 %
13.76 %
Jan 1, 2027 (e)
56.24 %
37.66 %
20.76 %
Jan 1, 2028 (e)
56.24 %
25.66 %
21.93 %
Jan 1, 2029 (e)
56.24 %
23.83 %
22.04 %
Jan 1, 2030 (e)
56.24 %
23.88 %
22.49 %
Teleflex Stock analysis
What does Teleflex do? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care.
The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors.
Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients.
In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths.
The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources.
The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies.
With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths.
The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators.
The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials.
The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents.
Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Teleflex stock
Gross Profit of Teleflex is 1.12 B USD in 2026.
Access this data via the Eulerpool API
Income Statement — Teleflex
All Key Metrics — Teleflex
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth